Pandemic-era NIH grants (FY2019-2024) covering coronavirus, gain-of-function research, mRNA vaccines, biosafety, and related funding flows. Metadata + abstracts from NIH RePORTER.
Get an AI answer drawn only from the NIH Pandemic-Era Grants documents indexed here — every claim cited back to the filing or proceeding it came from. It will tell you plainly when the record doesn't cover your question, rather than guessing.
Anny Xiaobo Zhou · BRIGHAM AND WOMEN'S HOSPITAL · 2024 · $640,287 — Project Summary Respiratory virus infection, an increasing health and social burden alone, also increases risk for development and exacerbation of other respiratory diseases, including asthma that affects 17 million U.S. people. Viral infection triggers innate immune response, an important defensive…
KASI E RUSSELL-LODRIGUE · TULANE UNIVERSITY OF LOUISIANA · 2024 · $1,415,801 — Project Summary/Abstract - Overall The Tulane National Primate Research Center (TNPRC) has one of the largest rhesus monkey breeding colonies in the United States. The objective of this application is to request funds for continued support and maintenance of the U42 supported SPF Indian-origin rhesu…
Midori A Yenari · VETERANS AFFAIRS MED CTR SAN FRANCISCO · 2024 — This project will explore calcium-release-activated calcium channels (CRAC) as a potential therapeutic target in a laboratory model of traumatic brain injury (TBI). TBI is a common problem in the Veteran and civilian populations but definitive treatments are few. Microglia are the brain’s resident i…
Denise M. Hynes · PORTLAND VA MEDICAL CENTER · 2024 — Project Summary/Abstract As a VA Core Investigator at the HSR&D Center to Improve Veteran Involvement in Care and the Evidence Synthesis Program Coordinating Center based at the Portland VA Healthcare System, my current research activities include Scholarly Research, Training emerging scientists, a…
MARLENE BOUVIER · UNIVERSITY OF ILLINOIS AT CHICAGO · 2024 · $199,875 — ABSTRACT Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is responsible for the current pandemic of coronavirus-induced disease 2019 (COVID-19). Since December 2019, coordinated research efforts have provided a wealth of critical data that have enhanced our ability to diagnose and trea…
Christopher W Peterson · FRED HUTCHINSON CANCER CENTER · 2024 · $770,685 — ABSTRACT HIV-specific gene therapies are a powerful and promising means to achieve HIV cure/stable remission in the absence of antiretroviral therapy (ART). Broadly neutralizing antibodies (bNAbs) and analogous molecules such as eCD4-Ig offer one of the clearest paths to a cure, but are hindered by …
Jeannette Michele Beasley · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · 2024 · $676,710 — PROJECT ABSTRACT Over 24 million Americans are ≥65 years and have prediabetes. Prediabetes can be addressed using a public health approach: among the 20% of participants in the Diabetes Prevention Program (DPP) who were ages 60 and over, the diet and physical activity intervention conferred a 71% r…
Karen L. Kotloff · UNIVERSITY OF MARYLAND BALTIMORE · 2024 · $1,752,798 — Project Summary/Abstract The University of Maryland School of Medicine (UMSOM) Center for Vaccine Development and Global Health (CVD) has been an established VTEU site since 1974. The goal of the VTEUs is to initiate innovative concepts for clinical research and implement clinical site protocols for…
LAURA CONFORTI · UNIVERSITY OF CINCINNATI · 2024 · $215,846 — PROJECT SUMMARY Immune checkpoint inhibitors like monoclonal blocking antibodies against programmed cell death 1 (PD1) have revolutionized the way solid malignancies are treated. However, despite a dramatic response in some patients, the majority either have no response or develop resistance. The fo…
Jianxin You · UNIVERSITY OF PENNSYLVANIA · 2024 · $180,425 — Project Summary Tumor immune suppression represents a major obstacle in achieving effective cancer immunotherapy. The goal of this exploratory project is to develop a novel mRNA-lipid nanoparticle (mRNA-LNP)-based immunotherapy to overcome this challenge in pancreatic cancer, one of the deadliest ma…
Bradford J Smith · UNIVERSITY OF COLORADO DENVER · 2024 · $591,347 — Project Summary Acute respiratory distress syndrome (ARDS) is a rapid onset respiratory failure that is caused by factors ranging from pneumonia to sepsis. The impact of ARDS is substantial with more than 200,000 cases per year in the United States and an estimated mortality rate of 40%. All ARDS pa…
Alison Cohen · FORDHAM UNIVERSITY · 2024 · $597,445 — Emerging adulthood represents a uniquely sensitive period for studying social determinants of health in the United States (US), as young people begin to establish their own paths towards higher education, careers, and financial independence. College, specifically, is a time of changing socioeconomic…
Adolfo Garcia-Sastre · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · 2024 · $2,534,738 — Previous to the COVID-19 pandemic, we assembled, under the same U19 mechanism, a multidisciplinary team to obtain multiple OMICS-based systems level measurements and integrate them using modeling approaches and machine learning algorithms to identify and validate host-virus networks that modulate in…
Wan Yang · COLUMBIA UNIVERSITY HEALTH SCIENCES · 2024 · $205,625 — Using wastewater surveillance data to study SARS-CoV-2 dynamics and predict COVID-19 outcomes Due to the continued evolution of SARS-CoV-2 and emergence of new variants, COVID-19 will likely continue to impose a substantial public health burden in the United States in the future. Yet, the rollback o…
Jonathan Wynn · VA GREATER LOS ANGELES HEALTHCARE SYSTEM · 2024 — The COVID-19 Pandemic, which became widespread in the United States in March 2020, has directly impacted nearly everyone in our country. An exceptionally large number of Americans have contracted the SARS-CoV-2 virus. The long-term effects of being infected by the virus are unknown, but it is eviden…
Harvey Bruce Pollard · HENRY M. JACKSON FDN FOR THE ADV MIL/MED · 2024 · $574,708 — Abstract Over 860,000 COVID-19 deaths have occurred in the U.S., and more than 5.5 million deaths have occurred world-wide. Consequently, development of effective antiviral drugs that block infectivity and airway inflammation continue to be a global health priority. Inflammation in the COVID-19 air…
Charles M Rice · ROCKEFELLER UNIVERSITY · 2024 · $650,415 — Project Summary The current pandemic has highlighted fundamental gaps in our knowledge about the replication strategies of coronaviruses, and how these are affected by the host at both the organismal and cellular level. There is a pressing need to understand how SARS-CoV-2 infection and host-cell r…
Ali Hassan Ellebedy · WASHINGTON UNIVERSITY · 2024 · $593,729 — ABSTRACT mRNA-based vaccines use lipid nanoparticles to transport mRNA-encoding antigens to the host cells. We have recently shown that SARS-CoV-2 mRNA vaccination in humans induces a robust plasmablast response in blood and a persistent GC reaction in the draining lymph nodes. This corresponded wit…
ELAINE F REED · UNIVERSITY OF CALIFORNIA LOS ANGELES · 2024 · $605,731 — PROJECT SUMMARY/ABSTRACT Immunocompromised patients, including those requiring immunosuppressive therapy following organ transplantation, are at high risk for severe disease from SARS‐CoV‐2. As SARS-CoV-2 rapidly transitions from a pandemic virus to endemic status, like influenza, seasonal vaccinati…
STEPHEN C JAMESON · UNIVERSITY OF MINNESOTA · 2024 · $2,723,166 — SUMMARY The association between advanced age and impaired resistance to infections is well known, but poorly understood. The current COVID-19 pandemic is a clear example of the vulnerability of the elderly to SARS- CoV-2 infection as well as many other pathogens. Considerable research efforts have s…